WHO certifies new HIV treatment drug

| July 25, 2019 | 0 Comments

WHO certifies new HIV treatment drug


The World Health Organisation (WHO) has certified Dolutegravir (DTG) as a safe and preferred first-line and second-line treatment drug for HIV/AIDS, adding that pregnant women can also use it.

In a statement posted on its official website on Monday, it said initial studies had flagged DTG as having a possible link with neural tube defects (birth defects of the brain and spinal cord that cause conditions such as spina bifida) in infants born to women using the drug at the time of conception.

Consequently, based on these preliminary findings, many countries had advised pregnant women and women of childbearing potential to take efavirenz (EFV) instead, the release said.

“However, new data from two large clinical trials comparing the efficacy and safety of DTG and EFV in Africa have now expanded the evidence base.”

WHO said according to new data, risks of neural tube defects are significantly lower when using DTG than what the initial studies may have suggested.

The agency described DTG as an HIV drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used.

“DTG also has a high genetic barrier to developing drug resistance, which is important given the rising trend of resistance to EFV and nevirapine-based regimens.

“In 2019, 12 out of 18 countries surveyed by WHO reported pre-treatment drug resistance levels exceeding the recommended threshold of 10 per cent.

“All of above findings informed the decision to update the 2019 guidelines, and the newly updated recommendations aim to help more countries improve their HIV policies,” WHO said.

”For any medications, informed choice is important as every treatment decision needs to be based on an informed discussion with the health provider weighing the benefits and potential risks,” it said.

Advertisement



Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.3

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.

Donate

Ebuka Onyeji is a health reporter at PREMIUM TIMES. He also has a penchant for music and art. Ebuka holds a degree in Mass communication from Anambra State University.




DOWNLOAD THE PREMIUM TIMES MOBILE APP

Now available on

 


TEXT AD: This space is available for a Text_Ad.. Call Willie on +2347088095401 for more information


All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.


More in News Reports

Top News

Culled from :Here

We enjoin our readers to send their stories/articles/reports, including pictures to story@riversstatenews.com

Comments

comments

Category: Health